Management of Hyperlipidemia After Stroke

被引：12
作者：
Brooks, Daniel C. [1 ,2 ]
Schindler, Joseph L. [3 ]
机构：
[1] Stamford Hlth Med Grp, Dept Internal Med, Div Neurol, Stamford, CT USA
[2] Stamford Hosp, Stamford, CT USA
[3] Yale Univ, Sch Med, Dept Neurol, POB 208018, New Haven, CT 06520 USA
来源：
CURRENT TREATMENT OPTIONS IN CARDIOVASCULAR MEDICINE | 2019年 / 21卷 / 12期
关键词：
Stroke; TIA; ICH; LDL-C; Hyperlipidemia; Dyslipidemia;
D O I：
10.1007/s11936-019-0774-8
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
Purpose of review Hyperlipidemia is a key therapeutic target for stroke risk modification. The goal of this review is to highlight available treatment options and review their efficacy in the setting of general cardiovascular disease and after most subtypes of ischemic stroke and hemorrhagic stroke. Recent findings Statins remain first-line in the management of hyperlipidemia to prevent stroke. In recent trials of patients with pre-existing atherosclerotic vascular disease, new agents, most notably PCSK9 inhibitors and ezetimibe, added additional stroke risk reduction when combined with statins. Risk of stroke can be significantly reduced by understanding that hyperlipidemia is a key therapeutic target, particularly in patients with cardiovascular disease, and by identifying patients who may benefit from aggressive LDL-C reduction with statins +/- novel agents.
引用
收藏
页数：15
相关论文
共 89 条
[1]  
Cardiovascular Diseases Fact Sheet, (2017)
[2]  
Benjamin E.J., Et al., Heart disease and stroke statistics-2019 update: a report from the American Heart Association, Circulation, 139, 10, pp. e56-e528, (2019)
[3]  
Vangen-Lonne A.M., Et al., Declining incidence of ischemic stroke: what is the impact of changing risk factors? The Tromsø Study 1995 to 2012, Stroke, 48, 3, pp. 544-550, (2017)
[4]  
Peters S.A., Et al., Total cholesterol as a risk factor for coronary heart disease and stroke in women compared with men: a systematic review and meta-analysis, Atherosclerosis, 248, pp. 123-131, (2016)
[5]  
Ganda O.P., Et al., Unmet need for adjunctive dyslipidemia therapy in hypertriglyceridemia management, J Am Coll Cardiol, 72, 3, pp. 330-343, (2018)
[6]  
Varbo A., Nordestgaard B.G., Remnant cholesterol and risk of ischemic stroke in 112,512 individuals from the general population, Ann Neurol, 85, 4, pp. 550-559, (2019)
[7]  
Jepsen A.M., Et al., Increased remnant cholesterol explains part of residual risk of all-cause mortality in 5414 patients with ischemic heart disease, Clin Chem, 62, 4, pp. 593-604, (2016)
[8]  
Baigent C., Et al., Efficacy and safety of more intensive lowering of LDL cholesterol: a meta-analysis of data from 170,000 participants in 26 randomized trials, Lancet, 376, 9753, pp. 1670-1681, (2010)
[9]  
Kurth T., Et al., Lipid levels and the risk of ischemic stroke in women, Neurology, 68, 8, pp. 556-562, (2007)
[10]  
Imamura T., Et al., LDL cholesterol and the development of stroke subtypes and coronary heart disease in a general Japanese population: the Hisayama study, Stroke, 40, 2, pp. 382-388, (2009)
123456789